STUDY OF PEG 3350 IN THE PEDIATRIC POPULATION

Williams, K1; Rogers, L2; Yin, H2; Hill, I1; Barnard, J 1, 2; Coss, C3; DiLorenzo, C1

1Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, OH
2Research Institute at Nationwide Children's Hospital, Columbus, OH
3College of Pharmacy, Ohio State University, Columbus, OH

Disclosures

No financial relationships to disclose

Background

• Reports of “neuropsychiatric events” associated with polyethylene glycol (PEG 3350) 3350

• “Potential neurotoxic contaminants”
  – ethylene glycol (EG)
  – diethylene glycol (DEG)
  – triethylene glycol (TEG)
Purpose of Study

Determine if EG, DEG, and/or TEG are elevated in the blood of children treated with PEG 3350

Study Participants

• Inclusion
  – Functional Constipation
  – 7-12 years of age
  – One capful (17gram) for ≥2 weeks
• Exclusion
  – Physiological disorder of GI tract
  – Prior abdominal surgery
  – Psychiatric and behavioral disorders
• 9 participants
• 18 age/sex matched healthy controls

Study Design

• Morning visit prior to PEG 3350 dose
• Measure 2 doses of “home” PEG 3350
  – 1 for participant
  – 1 in glass container for analysis
• Blood samples
  – Placed IV
  – Baseline blood sample
  – Gave PEG 3350 dose
  – Blood samples at 30, 60, 90, 120, 150, and 180 min.
Sample Analysis

- Serum
- PEG 3350 (suspended in city tap water)
- City tap water

- Liquid chromatography – mass spec/mass spec (LC-MS/MS)
  based upon published methods

Do Baseline Levels Differ Between Groups?

Baseline Levels: Ethylene Glycol

<table>
<thead>
<tr>
<th>Blood Levels (ng/ml)</th>
<th>Control</th>
<th>PEG Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>p = 0.82</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>600</td>
<td></td>
<td></td>
</tr>
<tr>
<td>800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1600</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2400</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


db
Baseline Levels: Diethylene Glycol

Baseline Levels: Triethylene Glycol

Do Baseline Blood Levels Increase After PEG 3350 Dose?
Ethylene Glycol

- Graph showing concentration over time
- Peak at 150 minutes
- Significance levels: p=0.006, p=0.018

Diethylene Glycol

- Graph showing concentration over time
- Steady concentration levels over time

Triethylene Glycol

- Graph showing concentration over time
- Peak at 50 minutes
- Significance levels: p=0.0057, p=0.031
Do PEG 3350 samples contain EG, DEG, and/or TEG?

Levels in PEG 3350 Doses

Does Water Contain EG, DEG, and/or TEG?
Summary

Chronic use of PEG 3350 not associated with sustained elevation of EG, DEG or TEG blood levels

DEG levels significantly lower in PEG 3350 group

EG and TEG blood levels increased after taking PEG 3350

EG and TEG detected in PEG 3350 samples

Discussion

800 µg/kg/day is minimal risk level for EG from daily environmental exposure for intermediate-duration (15-364 days)

(U.S. Department of Health and Human Services)

Effect on development from low level environmental exposures is unknown

Further studies are needed
Discussion

800 µg/kg/day is minimal risk level for EG from daily environmental exposure for intermediate-duration (15-364 days)
(U.S. Department of Health and Human Services)

Effect on development from low level environmental exposures is unknown

Further studies are needed - Not just on PEG 3350